With two regulators looking on, IR at life sciences companies is getting a lot more complex.
Unlike other heavily regulated industries in the US, the stakes seem more dramatic in the high-risk life sciences sector becauseit is under the watch of two federal regulators: the SEC and the Food and Drug Administration (FDA). ‘Biotechs are subject to more scrutiny than most companies because of the FDA,’ acknowledges Arthur Gabinet, district administrator of the SEC’s Philadelphia office. ‘Because biotech companies’ financial futures are so heavily dependent
You need to register to access 3 free deep dive articles per month. To continue reading please register or login below..
- Unlimited deep dives
- Data-driven research around key topics
- Buy-side insights
- Benchmarking reports
From
$1495
Betsy Pisik
Award winning journalist, staff and freelance writer, ghost writer, speech writer, researcher
